SCHEDULE 13G/A: Capital Research Global Investors Amends Passive Stake in Haemonetics Corp., Holding 3.1% of Common Stock

Capital Research Global Investors has filed an Amendment No. 4 to Schedule 13G, disclosing a continued 3.1% beneficial ownership stake in Haemonetics Corp. as of March 31, 2025.

Summary

• Capital Research Global Investors (CRGI) filed an Amendment No. 4 to Schedule 13G, updating its beneficial ownership in Haemonetics Corp.
• As of March 31, 2025, CRGI beneficially owned 1,577,323 shares of Haemonetics Corp. Common Stock.
• This ownership represents 3.1% of the 50,237,466 shares of Common Stock believed to be outstanding.
• CRGI holds sole voting power and sole dispositive power over all 1,577,323 shares.
• The filing certifies that the securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The filing is a routine disclosure of beneficial ownership by a major institutional investor, indicating continued, stable investment without any stated intent to influence control. The maintenance of a significant stake by a reputable investor can be seen as a minor positive signal.

Positives

• A significant institutional investor, Capital Research Global Investors, maintains a substantial stake in Haemonetics Corp., indicating continued confidence in the company as a passive investment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holding, which can offer some stability or confidence in the company's long-term prospects.

Key Dates

Keywords

Haemonetics Corp., Capital Research Global Investors, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, HAE